Medically reviewed by Jurairat J. Molina, MD Acute urticaria (hives) is a common skin condition that affects up to 20% of people at some point in their lives. It can transition into chronic urticaria ...

In May 2024, Novartis announced new data that confirm the long-term efficacy and safety of remibrutinib, a highly selective ...

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm ...

Chronic spontaneous urticaria is an inflammatory skin disease that causes hives that last for at least six weeks. Derms ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

While medications and medical conditions can cause hives ... “Urticaria: A comprehensive review, Treatment of chronic urticaria, special populations, and disease outcomes.” J Am Acad Dermatol. 2018;79 ...

"Physicians face multiple challenges in the management of chronic spontaneous urticaria, including inconsistent measures of treatment success ... and access to drugs for CSU play a significant ...

Celldex Therapeutics, Longbio Pharma, Celltrion, Enanta Pharmaceuticals, Evommune, and others are evaluating new urticaria drugs to improve the treatment landscape. Promising pipeline urticaria ...

The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric ...